An observational study in Pregnancy Related, sponsored by University Hospital, Montpellier. Terminated at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by University Hospital, Montpellier · Observational
Among 56 studies in Congenital Abnormalities with a site in France — 10 open to participants now, 13 under way, none of them phase 3. Congenital Abnormalities · France.
Among the 56 studies in Congenital Abnormalities with a site in France, this one is the 14th largest by enrollment of the 24 observational ones, is one of 5 that started in 2019, is one of 24 observational ones, and was the 37th registered.
781 studies on the registry are indexed under Congenital Abnormalities; 77 are open to participants now.
This study's enrollment of 77 is below the median of 250 across 257 observational studies indexed under Congenital Abnormalities.
Browse Congenital Abnormalities studies →10 of the 56 studies in Congenital Abnormalities with a site in France are open now, in 6 countries. Each count lists the studies.
Of the 60 Congenital Abnormalities studies recruiting now, 27 (45%) set no upper age limit and 27 (45%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →56 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2019.
Median enrollment 102 across the 32 interventional studies, 95 across the 24 observational. Of the 37 that completed or were terminated, 0 (0%) have results posted.
9 of 56 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.
University Hospital, Montpellier has 3 studies filed under Congenital Abnormalities — fewer than ten, so there is no comparison to draw.
2 of the studies in Congenital Abnormalities with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
| NCT06628375University Hospital, MontpellierA Multimodal Study of the Relationship Between Exposure to Endocrine Disruptors and Occurrence of Hypospadias - HYPOLLUT | 2027-09-30 |
Among the 56 studies in Congenital Abnormalities with a site in France, from their registry updates:
The aims of this study are:
Introduction: Intestinal malrotation is a rare congenital anomaly resulting from abnormal rotation and fixation of the intestine during embryonic development. It is rarely asymptomatic and most often presents in the neonatal period with obstructive complications, including duodenal obstruction and, most critically, midgut volvulus. Midgut volvulus constitutes a surgical emergency due to the risk of extensive intestinal ischemia and necrosis, which may lead to short bowel syndrome or death.
Currently, there is no prenatal screening strategy for intestinal malrotation, and the feasibility and diagnostic performance of third-trimester obstetric ultrasound for detecting intestinal malrotation have never been formally evaluated.
Aim: To evaluate the diagnostic performance of third-trimester obstetric ultrasound in identifying the intestinal structures involved in high-risk intestinal malrotation associated with volvulus, using fetal MRI as the reference standard.
Methods : Eligible pregnant women will be identified during routine obstetric follow-up at Nîmes or Montpellier University Hospitals and enrolled exclusively in Montpellier. Each participant will undergo a third-trimester obstetric ultrasound and fetal MRI on the same day. Examinations will be performed independently by a senior obstetrician and a senior pediatric radiologist, both blinded to the other modality. Ultrasound visualization of mesenteric vessels, small bowel, and cecum will be compared with fetal MRI findings as the reference standard. Interobserver agreement for ultrasound interpretation will be assessed, and analyses will be stratified by gestational age. Participation duration is one day.
Pregnant women with normal intestinal structure and requiring a fetal MRI for other reason
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All pregnant women with a pregnancy of at least 31 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures, will be proposed inclusion in the study.
Other: Reference ultrasound examination
Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
Also known as: Fetal MRI, Comparison of both results
Ultrasound localization of intestinal structure (mesenteric vessels, small bowel, gut)
The primary outcome will be ultrasound localization of intestinal structure (mesenteric vessels, small bowel, gut)
Time frame: At the visit 1 of the subjects
normal meconium progression
Normal meconium progression will be described by the results of ultrasound examination and MRI
Time frame: At the visit 1 of the subjects
Plan to share: No
Ran from Nov 2019 to primary completion in Apr 2023, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →